Perimenopause Racial and Ethnic Disparities: What the Evidence Shows

Why Race and Ethnicity Shape Perimenopause Differently

Race and ethnicity predict perimenopause timing, symptom severity, and care quality in ways that cannot be attributed to biology alone. Socioeconomic stress, neighborhood environment, lifetime allostatic load, and systemic barriers to care each compound biological variation to produce the disparities measured in cohort data.

The SWAN Study: The Primary Evidence Base

The Study of Women's Health Across the Nation (SWAN) enrolled 3,302 premenopausal women aged 42 to 52 across seven U.S. Sites beginning in 1996, including self-identified Black, Hispanic, Chinese, Japanese, and white participants [1]. No other longitudinal dataset comes close to SWAN's depth for this question. Results published across its follow-up periods show consistent, statistically significant differences by race and ethnicity in nearly every perimenopause domain measured.

SWAN data published in the American Journal of Obstetrics and Gynecology confirmed that Black women experienced a significantly longer vasomotor symptom (VMS) duration, a median of 10.1 years, compared to 6.5 years for white women [2]. Chinese and Japanese women reported the shortest VMS duration. These differences persisted after adjustment for BMI, smoking, physical activity, and education level [2].

Allostatic Load and Biological Weathering

Allostatic load, the cumulative physiological cost of chronic stress, is higher in Black women than in white women of comparable age, a pattern researchers refer to as "weathering" [3]. Higher allostatic load is associated with earlier reproductive aging and more pronounced HPA-axis dysregulation, which may amplify thermoregulatory instability during perimenopause [3].

A 2021 study in Menopause found that Black women had significantly elevated allostatic load scores compared to white women in the SWAN cohort, and that this difference accounted for a portion, though not all, of the VMS disparity [4]. Biology and social context interact here; they are not separable.

Age at Menopause Onset Varies by Race

Natural menopause occurs earlier in Black women than in white, Hispanic, Chinese, or Japanese women. This gap is clinically meaningful because it affects the window for preventive cardiovascular and bone protection.

Documented Differences in Onset Timing

SWAN data show Black women reach natural menopause at a median age of 49.0 years versus 51.4 years for white women, a difference of approximately 8.5 months after covariate adjustment [5]. Hispanic women reach menopause at a median age of 49.9 years. Chinese and Japanese women are closest to white women at approximately 51.8 years [5].

Earlier menopause increases cumulative years of estrogen deficiency, which raises the absolute risk of cardiovascular disease, osteoporosis, and cognitive decline [6]. A 2022 analysis in JAMA Network Open found that each year of earlier menopause onset was associated with a 3% increase in cardiovascular event risk in Black women, a larger effect size than in white women [6].

Premature Ovarian Insufficiency Rates

Premature ovarian insufficiency (POI), defined as ovarian failure before age 40, affects approximately 1% of the general population but appears more common in Black women [7]. A population-based analysis using the Nurses' Health Study II found that Black women had a 1.5-fold higher rate of POI than white women after adjustment for reproductive history and BMI [7]. This has direct implications for fertility counseling and long-term hormone replacement, since women with POI have a longer duration of estrogen deficiency than those with typical menopause timing.

Vasomotor Symptom Burden Differs Substantially

Hot flashes and night sweats are not distributed equally. Black women report the highest frequency and severity; Japanese and Chinese women report the lowest. This is one of the most replicated findings in menopause research.

Frequency and Severity Data

In SWAN, 45.6% of Black women reported frequent hot flashes (6 or more per day) compared to 31.2% of white women [2]. After full covariate adjustment including BMI, smoking, hormone levels, and socioeconomic status, Black race remained an independent predictor of VMS frequency, with an odds ratio of 1.6 (95% CI 1.3 to 2.0, P<0.001) [2].

Asian subgroups show the opposite pattern. Fewer than 20% of Chinese and Japanese SWAN participants reported frequent hot flashes, even though measured estradiol levels did not differ substantially from other groups [1]. Researchers have proposed cultural differences in symptom reporting, dietary factors including phytoestrogen intake, and lower average BMI as partial explanations, though none fully accounts for the gap [8].

Night Sweats and Sleep Architecture

Night sweats disrupt slow-wave sleep and reduce total sleep time. Black women in SWAN reported a 70% higher prevalence of sleep-new night sweats compared to white women [9]. Objective actigraphy data from the SWAN Sleep Study confirmed that Black women had longer sleep latency, more nighttime awakenings, and lower sleep efficiency, independent of hot flash frequency [9].

Japanese and Chinese women reported fewer nocturnal symptoms but had higher rates of early morning awakening in actigraphy data, suggesting different sleep disruption patterns that may go underreported in standard symptom questionnaires [9].

Depression and Mood During the Perimenopause Transition

Perimenopause is a period of elevated depression risk across all groups, but the risk pattern differs by ethnicity in ways that standard screening tools may miss.

Hispanic Women and Depressive Symptoms

SWAN data show that Hispanic women score significantly higher on the Center for Epidemiologic Studies Depression Scale (CES-D) during the perimenopause transition than white women, after adjustment for life stress, social support, and economic strain [10]. A 2019 analysis in Depression and Anxiety found that Hispanic women were 1.4 times more likely to report clinically significant depressive symptoms during perimenopause than white women, with acculturation stress identified as a contributing variable [10].

Black Women and Anxiety Burden

Black women in SWAN showed elevated anxiety scores on the Spielberger Trait Anxiety Inventory compared to white and Asian participants [11]. Chronic hypervigilance related to racial discrimination is thought to contribute to elevated baseline sympathetic tone, which may lower the threshold for both VMS and anxiety symptoms [11]. A 2020 paper in Psychosomatic Medicine found that self-reported experiences of everyday discrimination predicted both higher VMS frequency and higher anxiety scores in Black perimenopausal women, independent of socioeconomic status [12].

Cultural Differences in Symptom Framing

Japanese and Chinese women report lower rates of psychological symptoms on Western depression scales but higher rates of somatic complaints including shoulder stiffness, fatigue, and palpitations [13]. The Kupperman Index, designed in the 1950s, captures some somatic symptoms but was not validated in Asian populations and may undercount burden in these groups [13]. Clinicians using only VMS-focused questionnaires risk systematically undercounting symptom burden in East Asian patients.

Bone Density and Fracture Risk Across Ethnicities

Bone loss accelerates during perimenopause, but baseline bone density and fracture risk differ substantially by race.

Higher Baseline BMD in Black Women

Black women have, on average, 10 to 15% higher bone mineral density (BMD) than white women at baseline, a difference that persists into late perimenopause [14]. As a result, clinical osteoporosis and fragility fracture rates are lower in Black women than in white or Asian women at equivalent ages [14]. DXA screening guidelines historically used white women as the reference population, which may lead to underestimation of bone loss velocity in Black women even when absolute BMD remains above the diagnostic threshold for osteoporosis [15].

Asian Women and Fracture Risk

Asian women have lower baseline BMD than white women and comparable or higher age-adjusted fracture rates in some populations, despite lower clinical diagnosis rates [15]. A USPSTF review noted that fracture risk assessment tools such as FRAX were developed primarily in European populations and may underestimate 10-year fracture probability in Asian women [16].

Treatment Access and the Prescription Gap

The gap in hormone therapy (HT) prescribing is among the most consequential disparities in perimenopause care. Black women who stand to benefit the most from symptom relief are the least likely to receive it.

Prescription Rate Data

A 2021 cross-sectional analysis of 18,799 U.S. Women published in Menopause found that Black women were 40% less likely than white women to be prescribed menopausal hormone therapy, even after controlling for symptom severity, BMI, and insurance status [17]. Hispanic women were 28% less likely to receive a prescription than white women in the same analysis [17].

These differences persist within insured populations. A separate analysis of commercial insurance claims data covering 112,000 women found that Black women with documented severe VMS had a prescription fill rate of 22% for HT, compared to 38% for white women with the same documented severity [18].

Provider Bias and Communication Barriers

Qualitative research published in Menopause in 2020 found that Black women reported feeling dismissed by providers when raising menopause symptoms, with several describing experiences in which clinicians attributed their symptoms to stress or weight rather than reproductive transition [19]. These findings align with broader literature on racial disparities in pain assessment and treatment in U.S. Healthcare settings [19].

The 2023 Menopause Society Position Statement states: "Clinicians should be aware that racial and ethnic minority women face unique barriers to menopause care including underdiagnosis, undertreament, and inadequate counseling, and should proactively screen all women for menopausal symptoms regardless of perceived risk." [20]

Non-Hormonal Options and Equitable Access

The FDA approved fezolinetant (Veozah), a neurokinin 3 receptor antagonist, in May 2023 for moderate-to-severe VMS in menopause [21]. Clinical trials for fezolinetant enrolled a more diverse population than most prior menopause trials: 16% of participants in SKYLIGHT 1 and SKYLIGHT 2 were Black, and 14% were Hispanic [22]. Efficacy and safety profiles were consistent across racial subgroups [22]. For women with contraindications to estrogen, including some breast cancer survivors, fezolinetant represents a new option. Paroxetine 7.5 mg (Brisdelle), the only SSRI with FDA approval specifically for VMS, also showed consistent efficacy across racial groups in its registration trials, though the dataset was smaller [23].

Guidelines and Clinical Recommendations

Multiple professional societies now address race-specific considerations in perimenopause care, though implementation remains inconsistent.

The Menopause Society (TMS) 2023 Position Statement

The Menopause Society's 2023 Position Statement on hormone therapy explicitly notes that the benefits of HT for VMS management likely outweigh risks for most women under age 60 or within 10 years of menopause onset, regardless of race [20]. The statement adds that shared decision-making should incorporate individual cardiovascular, breast cancer, and thrombotic risk rather than applying population-level assumptions based on race.

Endocrine Society Clinical Practice Guideline

The Endocrine Society's guideline on menopause hormone therapy, updated in 2015 and under revision, recommends against withholding HT based on race or ethnicity alone [24]. It supports FSH and estradiol measurement to confirm menopausal status in women with irregular cycles, which is particularly relevant for Black women who may reach perimenopause earlier.

ACOG Practice Bulletin

ACOG Practice Bulletin No. 141 on the management of menopausal symptoms recommends that clinicians assess symptom burden using validated tools such as the Menopause Rating Scale or the Greene Climacteric Scale, and notes that these tools may perform differently in non-white populations [25]. ACOG explicitly calls for further research on menopause symptom assessment instruments validated across racial and ethnic groups [25].

Cardiovascular Risk During Perimenopause by Race

The perimenopausal years represent a window of accelerating cardiovascular risk. This risk is not distributed equally.

Black Women and Hypertension During Transition

Black women have substantially higher rates of hypertension than white women, and blood pressure tends to rise more steeply during the perimenopause transition [26]. A SWAN analysis found that systolic blood pressure increased by a mean of 5.3 mmHg more in Black women than in white women during the menopausal transition, even after adjustment for BMI change and physical activity [26].

The American Heart Association's 2020 scientific statement on cardiovascular disease in women notes that Black women have the highest cardiovascular mortality of any female demographic group in the U.S., and that the perimenopause transition years represent a window during which risk factor management could meaningfully reduce lifetime cardiovascular burden [27].

Metabolic Changes and Insulin Resistance

Perimenopause is associated with worsening insulin sensitivity in all women, but Hispanic women show particularly steep declines in insulin sensitivity during this transition [28]. SWAN data found that Hispanic women experienced a 15% greater decline in insulin sensitivity during the perimenopause transition than white women, after covariate adjustment [28]. This has direct implications for type 2 diabetes prevention and weight management counseling during the transition years.

Practical Clinical Takeaways

Clinicians seeing perimenopausal patients from racial and ethnic minority groups should adjust their clinical approach in several concrete ways.

Symptom Assessment

Use the Menopause Rating Scale (MRS) rather than VMS-only checklists. The MRS captures somatic, psychological, and urogenital domains, making it more sensitive to the full symptom burden in East Asian women, who tend to report somatic over vasomotor complaints [13]. For Spanish-speaking patients, the validated Spanish-language version of the MRS is available and preferred over ad-hoc translation [29].

Timing of Conversations

Given that Black women may enter perimenopause 1 to 2 years earlier than white women on average, clinicians should begin menopause transition counseling at age 42 to 43 in Black patients with irregular cycles rather than waiting for the conventional age-45 threshold [5].

Treatment Equity

Document symptom severity in the medical record using a validated scale score. This creates an objective basis for treatment decisions that is less susceptible to provider bias and provides a defensible rationale for prescribing HT in cases where under-prescribing might otherwise occur [17].

Systemic estradiol (oral 17-beta estradiol or transdermal estradiol patch) remains the most effective treatment for VMS [20]. For Black women with elevated cardiovascular risk or hypertension, transdermal estradiol is preferred over oral formulations because it avoids first-pass hepatic metabolism and does not increase thrombotic risk at standard doses [20].